Organisation paid for research Program year 2025 Source: CMS Open Payments

Care Institute LLC

Neither a doctor nor a teaching hospital

Research payments

$515,399

22 payments

Through program year 2025, Care Institute LLC is reported as receiving $515,399 in research payments, across 22 payments.

By program year

2 rows
Year Kind Amount Payments
2025 Research $420,218 16
2024 Research $95,181 6

Breakdown

Who paid Research payments · program years 2024–2025
  1. Eli Lilly and Company $377,207 7 payments
  2. Hoffmann-La Roche Limited $71,058 10 payments
  3. Amgen Inc. $27,453 1 payment
  4. Takeda Pharmaceuticals U.S.A., Inc. $20,100 3 payments
  5. AbbVie, Inc. $19,581 1 payment
Studies the money was for Research payments · program years 2024–2025
  1. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(A) Who Have Established Atherosclerotic Cardiovascular Disease Or Are at Risk for A First Cardiovascular Event - Acclaim-Lp(A) $242,001 3 payments
  2. A Phase 3, Randomized, Multicenter, Double-Blind Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared With Placebo in Adult Participants With Type 2 Diabetes, Moderate Or Severe Renal Impairment With Inadequate Glycemic Control on Basal Insulin With Or Without Metformin And/Or Sglt2 Inhibitor $135,048 3 payments
  3. Double blind study to determine efficacy of ASO Factor B in IgAN $71,058 10 payments
  4. A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF) $27,453 1 payment
  5. A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition $20,100 3 payments
  6. A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD) $19,581 1 payment
  7. A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease $158 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record